Accelerator

50 Partners

Founded 2012 by 50 entrepreneurs. Accelerator offering hands-on mentorship and seed investment for tech, impact, and healthtech ventures; the mentor network includes founders behind BlaBlaCar, Le Bon Coin, and Showroomprivé.

Support: equity investment, mentorship, Paris workspace. Scope: National.

FranceParisTechImpactHealthTech

Back to directory Visit site

Details

Location

Paris, France

Similar entries

Matched by sector and location overlap

Alan

Paris, France · Startup

Modern health insurance platform streamlining getting care for European employees.

StartupGrowthHealthSoftware

View profile Visit site

Aptamedica

Warsaw, Poland · Startup

Warsaw-based medtech startup developing AptaSense, a bedside analyzer for near real-time therapeutic drug monitoring. The platform uses disposable strips to measure antibiotic and protein levels in around one minute to support precise dosing in sepsis and critical care.

StartupEarly StageMedTechDiagnosticsHealthTech

View profile Visit site

Bioptimus

Paris, France · Startup

Bioptimus is the self-proclaimed "Mistral of Biology," spun out in early 2024 by a team of alumni from Google DeepMind and Owkin, including CEO Jean-Philippe Vert. The company is building what it calls the first universal foundation model for biology. Where large language models were trained on text to learn human language, Bioptimus trains on biological data—DNA sequences, protein structures, cellular imagery, and clinical phenotypes—to infer the underlying rules of life. The ambition is not just better predictions but a unified biological reasoning layer that can simulate outcomes before expensive lab work happens. By 2026, Bioptimus has moved from a research thesis to early commercial traction. After a $41M Series A in 2025, the company released its first commercial model that can predict how a specific molecule will interact with a human cell with unusually high accuracy. This enables in-silico screening that reduces wet-lab costs and improves hit rates for drug discovery. French pharma leaders such as Sanofi have begun using these models to prioritize compounds and compress early-stage discovery timelines. The product value is immediate: fewer failed experiments, faster candidate selection, and deeper mechanistic insight. Bioptimus' roadmap focuses on "multi-scale biology," connecting the micro level (genomics and proteomics) to the macro level (patient outcomes and clinical data). Rather than being limited to protein folding, the models aim to bridge across data modalities so a genetic mutation can be linked to disease pathways, tissue behavior, and potential therapeutic interventions. This requires data breadth and regulatory trust, and Bioptimus is building a defensive moat through European data sovereignty. It leverages partnerships with European research hospitals and biobanks to access high-quality patient data that is difficult for US competitors to acquire under GDPR constraints. That compliance burden becomes a competitive advantage: safer access, better provenance, and stronger alignment with European health data governance. The company remains deeply embedded in the Paris ecosystem. It was incubated inside Owkin before spinning out, maintains a presence around Station F, and benefits from the cross-pollination between French AI and biotech communities. Its investor base reflects that positioning: Sofinnova Partners, Bpifrance, Cathay Innovation, Xavier Niel, and Frst provide a blend of life-science expertise, sovereign capital, and deep-tech conviction. In 2026, Bioptimus is the clearest European bet that foundation models can unlock biology at scale—and a contender to become the default AI layer for drug discovery in Europe.

StartupGrowthBiotechAIHealthcare

View profile Visit site

BlaBlaCar

Paris, France · Startup

BlaBlaCar is the world’s leading long-distance carpooling platform, often hailed as France’s flagship startup success. Founded in 2006 by Frédéric Mazzella (along with Francis Nappez and Nicolas Brusson), BlaBlaCar was born from Mazzella’s realization that countless car journeys had empty seats. The platform (named after users’ self-described chattyness level – “Bla”, “BlaBla”, or “BlaBlaBla”) connects drivers with spare seats to passengers traveling the same way, so they can share the ride and costs. Today, BlaBlaCar has a 100 million-member community across 22+ countries, serving over 25 million travelers per quarter pre-pandemic. It operates in most of Europe and parts of Latin America and Asia, having successfully localized carpooling in markets like Germany, Russia, Brazil, and Turkey. The company also branched into bus travel: in 2018, BlaBlaCar acquired Ouibus from SNCF, rebranding it BlaBlaBus, to offer intercity bus routes alongside carpool rides. BlaBlaCar’s business model charges a roughly 10–20% booking fee from passengers in mature markets, though in new markets it often launches free to build liquidity. Known for its strong community culture, BlaBlaCar emphasizes trust – it introduced verified profiles, ratings, and even an optional “Ladies Only” carpool option. The company achieved unicorn status in 2015 when it raised $200 million at a $1.6 billion valuation and later was valued around $2 billion. Despite the pandemic’s impact on travel, BlaBlaCar rebounded by 2022, even reporting profitability. In 2023, it raised €100 million in financing to fuel growth. BlaBlaCar is often cited in case studies (Harvard, etc.) as a pioneer of the sharing economy in Europe, proving that a people-powered platform can transform intercity transport. By bringing cost-effective travel to millions and fostering new friendships on the road, BlaBlaCar has truly brought “ridesharing” into the mainstream – and stands as one of Europe’s few consumer-tech unicorns with global reach.

StartupGrowthMobilityMarketplace

View profile Visit site